The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Much Is The Anthrax Vaccine Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?
The anthrax vaccine market has experienced consistent growth in recent years. It is projected to increase from $11.77 billion in 2025 to $12.33 billion in 2026, reflecting a compound annual growth rate (CAGR) of 4.7%. This expansion during the historic period can be ascribed to a high prevalence of anthrax in livestock, government-led vaccination campaigns, research advancements in immunology, limited vaccine production capacity, and heightened awareness of occupational exposure.
The anthrax vaccine market is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach $14.49 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.1%. Several factors will drive this growth during the forecast period, including the creation of recombinant and next-generation vaccines, an increasing need for both human and animal prophylaxis, improvements in vaccine delivery methods, the enlargement of biodefense initiatives, and partnerships between pharmaceutical and defense industries. Key trends anticipated for this period encompass enhanced vaccine formulations, broader immunization campaigns, breakthroughs in cold chain and storage solutions, strategies for biodefense and pandemic readiness, and vaccination programs led by government and military entities.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp
What Major Drivers Are Influencing Demand In The Anthrax Vaccine Market?
The increasing incidence of infectious diseases is anticipated to drive the expansion of the anthrax vaccine market in the future. Infectious diseases are illnesses stemming from pathogenic microorganisms like bacteria, viruses, parasites, or fungi. These can transmit directly or indirectly between individuals, frequently resulting in symptoms from mild to severe, and occasionally fatal, contingent on the specific pathogen and the host’s immune system. The widespread occurrence of these diseases is attributed to global population demographic shifts, increased urbanization, alterations in environmental conditions and land utilization, and evolving human conduct. While primarily used for protection against anthrax, the anthrax vaccine is also being researched for its broader potential in preventing other infectious diseases, focusing on its immunogenic traits and adaptability. For example, data from February 2023, provided by the US-based nonprofit Council on Foreign Relations, indicated that up to 75% of newly identified or emerging infectious diseases (EIDs) and 60% of all recognized infectious diseases originated from zoonotic sources. Furthermore, globally, zoonotic diseases are responsible for 2.7 million human deaths and 2.5 billion instances of illness annually. Consequently, the increasing incidence of diseases is propelling the expansion of the anthrax vaccine market.
What Major Segment Divisions Exist Within The Anthrax Vaccine Market?
The anthrax vaccine market covered in this report is segmented –
1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine
2) By Application Type: Animal Use, Human Use
3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels
Subsegments:
1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine
2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine
How Are Trends Shaping The Direction Of The Anthrax Vaccine Market?
Leading companies in the anthrax vaccine market are prioritizing the creation of new products and obtaining FDA authorizations for their vaccines to guarantee their safety, effectiveness, and accessibility for individuals facing potential anthrax exposure. FDA approval indicates that a vaccine has undergone thorough clinical trials and is validated as safe for public use, thereby guarding individuals against possible side effects. As an illustration, in July 2023, Emergent BioSolutions Inc., a biopharmaceutical company based in the US, received approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), formerly known as AV7909, from the U.S. Food and Drug Administration (FDA). This approval was founded on data from a Phase 2 study evaluating Cyfendus’s compatibility with antibacterial medications and Phase 3 clinical research that contrasted the vaccine’s immunogenicity and safety with BioThrax, the preceding anthrax vaccine. Moreover, advancing safer and more potent adjuvants is essential to resolve issues linked to reactogenicity and boost the overall efficacy of anthrax vaccines.
Which Companies Are Leading Innovation In The Anthrax Vaccine Market?
Major companies operating in the anthrax vaccine market are Emergent BioSolutions Inc., Indian Immunologicals Limited, GC Biopharma, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company Inc., Botswana Vaccine Institute, VECOL S.A., Biological E Limited, Serum Institute of India Pvt. Ltd., Panacea Biotec Ltd., China National Biotec Group, Sinovac Biotech Ltd., Instituto Butantan, Razi Vaccine and Serum Research Institute, Federal State Unitary Enterprise Microgen, KM Biologics Co. Ltd., Haffkine Bio-Pharmaceutical Corporation Ltd.
Read the full anthrax vaccine market report here:
https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report
Which Region Shows The Strongest Potential For Future Growth In The Anthrax Vaccine Market?
North America was the largest region in the anthrax vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Anthrax Vaccine Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=15511&type=smp
Browse Through More Reports Similar to the Global Anthrax Vaccine Market 2026, By The Business Research Company
Anthrax Vaccine Market Report 2026
https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report
Anthrax Vaccine Market Report 2026
https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report
Anthracycline Market Report 2026
https://www.thebusinessresearchcompany.com/report/anthracycline-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model